<DOC>
	<DOCNO>NCT02494167</DOCNO>
	<brief_summary>This research study use special blood cell call multiple tumor-associated antigen ( TAA ) -specific T cell ( new experimental therapy ) treat patient acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) come back , may come back , go away standard treatment , include allogeneic hematopoietic stem cell transplant ( HSCT ) . The investigator previously use sort therapy treat Hodgkin non-Hodgkin lymphoma infect Epstein-Barr virus ( EBV ) , virus cause infectious mononucleosis ( `` mono '' `` kiss disease '' ) , Epstein Barr virus ( EBV ) . EBV find cancer cell half patient Hodgkin non-Hodgkin lymphoma . This suggest may play role cause lymphoma . The cancer cell infect EBV able hide body 's immune system escape kill . The investigator previously test whether special white blood cell ( call T cell ) train kill EBV-infected cell could affect tumor , many patient investigator find give trained T cell cause complete partial response . In several lymphomas type cancer like AML MDS , cancer cell EBV . The however express protein target way . The investigator able infuse tumor-targeted cell 10 patient lymphoma EBV , see complete response . Importantly , treatment appear safe . Therefore , investigator want test whether investigator direct special T cell type cancer carry similar protein call tumor-associated antigen ( TAAs ) . These protein specific cancer cell , either show , show low quantity , normal human cell . The investigator grow T cell patient ' stem cell donor laboratory way train recognize tumor protein WT1 , NY-ESO-1 , PRAME , Survivin , express AML MDS cancer cell . The cell infuse least 30 day post-allogeneic stem cell transplant . In study , investigator want see whether cell able recognize kill cancer cell express protein . These donor-derived multiTAA-specific T cell investigational product yet approve U.S. Food Drug Administration The purpose study find large safe dose donor-derived tumor protein multiTAA-specific T cell patient AML MDS .</brief_summary>
	<brief_title>Administration Donor Multi TAA-Specific T Cells AML MDS ( ADSPAM )</brief_title>
	<detailed_description>To make donor derive multiTAA-specific T cell , investigator collect blood patient 's stem cell donor , mix donor 's T cell small piece tumor protein WT1 , PRAME , NY-ESO-1 , Survivin . These protein fragment stimulate donor T cell grow react protein way recognize kill cancer cell express protein . Once sufficient number multiTAA-specific T cell make , investigator test make sure target patient 's cancer cell , normal healthy cell . The multiTAA-specific T cell administer single intravenous ( IV ) infusion 10 minute . The patient 's cancer assess within 4 week prior T cell infusion , 4-6 week infusion . If least 4 week infusion change reduction number cancer cell measure bone marrow , decline cancer-specific marker blood , patient may receive six ( 6 ) additional dos T cell every 4-6 week . All treatment give Center Cell Gene Therapy Houston Methodist Hospital Texas Children 's Hospital . For least 4 week infusion , patient may receive anti-cancer treatment , radiation therapy , chemotherapy . Patients receive therapy take treatment able receive additional dos T cell . However , drug 5-azacytidine ( Vidaza ) , decitabine ( Dacogen ) , lenalidomide ( Revlimid ) allow infusion . This dose escalation study , mean begin , patient start low dose ( 1 3 different level ) T cell . Once dose level prof safe , next group patient start next high dose . This process continue 3 dose level study . If side-effects severe , dose lower T cell injection stop . Before treated , patient undergo series standard medical test : - Physical exam . - Blood test measure blood cell , kidney liver function . - Measurement AML/MDS ( do bone marrow biopsy blood test ) - Pregnancy test , patient female child . Patients undergo standard medical test T cell infusion : - Blood test measure blood cell , kidney liver function . - Measurement disease 4-6 week T cell infusion 8-12 week infusion ( do bone marrow biopsy blood test ) . Patients follow one year date last T cell infusion , investigator learn way T cell work , long T cell last body , assess immune response cancer . Patients receive additional dos T cell undergo test evaluation perform dose described . Patients contact year 4 additional year ( total 5 year follow-up ) evaluate disease response long-term .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Only patient receive infusion integrate Cell Gene Therapy ( CAGT ) Transplant program Texas Children 's Hospital ( TCH ) Houston Methodist Hospital ( HMH ) eligible study . 1 . Patients eligible receive donorderived multiTAAspecific T cell follow type allogeneic HSCT ; ( ) Adjuvant therapy AML/MDS ( Group A ) ( ii ) Treatment refractory/relapsed minimal residual AML/MDS disease ( Group B ) Residual disease time transplant post transplant relapse define PCR positivity , specific cytogenetic abnormality , abnormal population flow cytometry increase blast bone marrow biopsy peripheral blood . Minimal residual disease ( MRD ) define detection blood marrow follow : ( ) Any leukemia specific marker ( 8 ; 21 ) ; inv 16 ; ( 15 ; 17 ) , ( 9 ; 22 ) ( 4 ; 11 ) document patient 's leukemia cell pretransplant posttransplant evaluation . ( ii ) Expression leukemia associate antigen know marker residual disease like WT1 . ( iii ) A leukemiaspecific phenotype ( e.g . expression marker include CD13 and/or CD33 and/or CD117 and/or HLADR+ ) posttransplant level ≥ 0.01 % . ( ix ) Mixed donor chimerism ( &gt; 20 % ) . 2 . Life expectancy ≥ 6 week . 3 . Karnofsky/Lansky score ≥ 50 . 4 . Patient parent/guardian capable providing inform consent . 5 . Bilirubin ≤ 2X upper limit normal . 6 . AST ≤ 3X upper limit normal . 7 . ANC &gt; 5 x10^8/L time infusion . 8 . Serum creatinine ≤ 2X upper limit normal . 9 . Hgb &gt; 8.0 g/dL ( transfuse ) . 10 . Pulse oximetry &gt; 90 % room air . 11 . Sexually active patient must willing utilize one effective birth control method 6 month T cell infusion . Male partner use condom . 12 . Available donorderived multiTAAspecific T cell line . 13 . No investigational antineoplastic therapy one month prior entry study . 1 . Patients receive ATG Campath within 28 day infusion . 2 . Patients receive Donor Lymphocyte Infusion within 4 week plan T cell infusion . 3 . Less 30 day postallogeneic stem cell transplant . 4 . Severe intercurrent infection . 5 . Evidence GVHD &gt; Grade II . 6 . Pregnant lactating . 7 . Currently take corticosteroid ( &gt; 0.5 mg/kg/day prednisone equivalent ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MultiTAA Specific T cell</keyword>
</DOC>